Soluset Insulin Solution Treatment Algorithm (SISTA) for Hyperglycaemic Emergencies among Adults in Low Income Countries

Abstract

industrial processes to prevent reactions to the animal insulins by the patients on insulin therapy. This went on until the 1980s. Through genetic engineering and intensive researches, Eli Lilly Corporation mass-produced human insulin [5]. This was a paradigm shift in insulin pharmacotherapy. Organisms such as Escherichia coli and yeasts are being used to grow human insulin through the process of Deoxyribonucleic (DNA) technology [5]. The manufactured insulins are subjected to purification processes such as high performance liquid chromatography, gel filtration and x-ray crystallography to ensure quality control. By the mid 1990’s, researchers started working on the modification of the amino acid sequencing coded by the insulin gene so as to produce insulin with better pharmacokinetic and pharmacodynamic properties. These insulins are called analogue insulins. Examples of the analogue insulins include rapid actin insulins such as (lispro, aspart and glulisine), long acting insulins (such as detemir and glargine) and ultra-long acting insulins (such as degludec). Insulin can be administered subcutaneously, intramuscularly or intravenously. Oral insulins are still under intense research while inhaled insulins have not received clinical patronization compared Abstract Prevalence of diabetes mellitus is